Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alfacell (ACEL) -- Ignore unavailable to you. Want to Upgrade?

To: Fish who wrote (1390)	6/19/1998 1:31:00 PM
From: Greg Kevorkian	Respond to of 1533

Yes, I would also like to here some responses to Fish.

To: Fish who wrote (1390)	6/19/1998 1:33:00 PM
From: John Jenco	Respond to of 1533

Fish -- Up to this very moment of reading your post, I had never actually considered ACEL management's actions in light of a failure to produce Phase III clinical trial results that were insufficient to support a successful NDA. However, in following that line of reasoning, I confess that I am hard pressed to disagree with your scenario. Does anyone know if there are any specific conditions for NDA approval that might be 'show stoppers', other than demonstrated efficacy? I have heard sporadic reports from various third party sources that patients in the Phase III panc clinical trials are continuing to do well, by and large. Does anyone else have a source(s) that actually KNOWS to what extent this may or may not be true?? Pls send me your comments offline, if you feel more comfortable. Thx. --John

To: Fish who wrote (1390)	6/19/1998 3:07:00 PM
From: Tom Scozzafava	Read Replies (2) \| Respond to of 1533

Fish, I too have thought about this scenario -- delaying this (presumably futile) process so more insiders can slowly cash out. But the one part I cannot reconcile with this theory is Gail Fraser. That is, clearly she will be ruined if this is a fraud. She (to our knowledge) has not sold shares during all of this and isn't making a fortune in salary. I'm not saying she is or ever will be in the running for CFO of the year, but she's young and her career in the business world could be severely damaged if this is all just b.s. So basically, what's in this for her to perpetuate a fraud? I just don't see it. Also, Tina will benefit more if this stock goes up. I know, the data is what the data is, and these actions (expressed in your theory) could simply be her best alternative. But obviously, she'll be rich beyond anyone's dreams if this stock goes up. And again, why would Gail effectively kill her own career for Tina?

To: Fish who wrote (1390)	6/19/1998 9:42:00 PM
From: Greg Kevorkian	Read Replies (1) \| Respond to of 1533

Fish, where did you see that the trials are unblinded. If data is that bad, how do we account for the positive published P2 data. Also the Oncology group in LA claims that the drug is 40% more effective for Meso than what's is available now.